Journal of Genetic Syndromes & Gene Therapy
Open Access

Recent Advances in Diagnosis of Down Syndrome Using Molecular Techniques

Harper Westwood^{* *}Correspondence: Harper Westwood, Department of Clinical Laboratory, University of Pennsylvania, Philadelphia, USA, Email:

Author info »

Description

Down Syndrome (DS) is a genetic disorder caused primarily by trisomy of chromosome 21, resulting in an extra copy of this chromosome in affected individuals. This chromosomal anomaly leads to a spectrum of clinical manifestations including intellectual disability, distinct facial features, and various congenital anomalies. Accurate and early diagnosis is essential for effective management and genetic counseling. Traditional diagnostic methods such as karyotyping have long been the standard; however, they are time-consuming and require invasive sampling. In recent years, molecular techniques have emerged as powerful tools that offer faster, more sensitive, and less invasive alternatives for diagnosing Down syndrome [1].

One of the earliest molecular methods to improve DS diagnosis was Fluorescence In Situ Hybridization (FISH). This technique uses fluorescently labeled DNA probes that specifically bind to sequences on chromosome 21, allowing visualization of chromosomal abnormalities under a fluorescence microscope [2]. FISH enables rapid detection of trisomy 21 within 24 to 48 hours and requires fewer cells compared to conventional karyotyping. This makes it particularly useful for prenatal diagnosis following procedures like amniocentesis or chorionic villus sampling. Despite its speed, FISH is limited by its targeted approach, as it can only detect abnormalities within the regions complementary to the probe, and it does not provide a comprehensive view of the entire chromosome set [3].

Quantitative Polymerase Chain Reaction (qPCR) has further advanced the molecular diagnosis of Down syndrome. This technique amplifies specific DNA sequences, enabling the quantification of DNA copy number variations on chromosome 21. qPCR offers high sensitivity and can be used on small DNA samples, making it suitable for both prenatal and postnatal testing [4]. Furthermore, qPCR can target specific genes on chromosome 21 known to be involved in the clinical features of DS, such as Amyloid Precursor Protein (APP) and DYRK1A, which influence neurodevelopment. Accurate quantification through qPCR aids in confirming the presence of trisomy 21 and can assist in research exploring genotype-phenotype correlations [5].

Another notable technique is Multiplex Ligation-dependent Probe Amplification (MLPA), which allows the simultaneous analysis of multiple genes for copy number changes. MLPA uses probes that hybridize to adjacent sequences on target genes, followed by ligation and PCR amplification. This method can detect partial trisomies, duplications, or deletions within chromosome 21 with high precision. MLPA’s multiplexing ability reduces the time and cost of testing and provides detailed information on specific regions of the chromosome, enhancing our understanding of how variations in gene dosage contribute to the phenotype of Down syndrome [6].

Perhaps the most revolutionary advancement in recent years has been the application of Next-Generation Sequencing (NGS) technologies. NGS enables high-throughput sequencing of entire genomes or targeted regions, allowing comprehensive detection of chromosomal abnormalities including trisomy 21 and mosaicism. A key application of NGS in Down syndrome diagnosis is Non-Invasive Prenatal Testing (NIPT), which analyzes cell-free fetal DNA circulating in maternal blood. NIPT offers exceptional sensitivity and specificity (over 99%) for detecting trisomy 21 as early as 10 weeks of gestation, significantly reducing the need for invasive diagnostic procedures [7]. This has transformed prenatal screening by providing a safer, faster, and highly accurate method for early detection.

Beyond detecting chromosomal abnormalities, molecular research has explored epigenetic modifications and molecular biomarkers associated with Down syndrome [8-10]. Studies of DNA methylation patterns, microRNAs, and other regulatory molecules offer promising avenues to improve diagnosis and understand the variability in clinical presentation. These emerging biomarkers could eventually complement existing molecular techniques, providing a more nuanced assessment of DS risk and prognosis. While these molecular advances have greatly enhanced the diagnosis of Down syndrome, challenges remain in terms of accessibility and cost, particularly in resource limited settings. Additionally, the ethical implications of early prenatal diagnosis and genetic counseling must be carefully navigated to respect patient autonomy and support informed decision-making.

Conclusion

Recent molecular techniques such as FISH, qPCR, MLPA, and NGS have significantly improved the speed, accuracy, and safety of Down syndrome diagnosis. These methods allow for early detection and better characterization of trisomy 21, facilitating timely clinical intervention and genetic counseling. Ongoing research into molecular biomarkers and epigenetic factors holds promise for even more precise and personalized diagnostic approaches in the future. As these technologies continue to evolve and become more accessible, they will play an increasingly important role in the management and understanding of Down syndrome.

References

1. Miner JH. Organogenesis of the kidney glomerulus: Focus on the glomerular basement membrane. Organogenesis. 2011;7(2):75-82.

   [Crossref] [Google Scholar] [PubMed]

2. Granholm AC. Vertebrate and invertebrate animal models for the study of down syndrome. Int J Mol Sci. 2025;26(16):8092.

   [Crossref] [Google Scholar] [PubMed]

3. Sabel G, Ahmadi A, Podder D, Stala O, Hirani R, Etienne M. Association between hypothyroidism and depression in individuals with Down syndrome: A retrospective analysis. Life. 2025;15(8):1199.

   [Crossref] [Google Scholar] [PubMed]

4. Petrilli PH, Rodrigues JV, Santos MJ, Paino-Sant’Ana A, Wainwright M, Garcia VG, et al. Adjunctive methylene blue-based antimicrobial photodynamic therapy in the re-instrumentation of residual periodontal pockets in individuals with Down syndrome: A randomized controlled clinical trial. J Dent. 2025:106061.

   [Crossref] [Google Scholar] [PubMed]

5. Park Y, Kil HR, Kim SY, Kim G. A rare case of aortic dissection 10 years post percutaneous catheterization retrieval of an embolized PDA device in a patient with Down syndrome. Pediatr Rep. 2025;17(4):84.

   [Crossref] [Google Scholar] [PubMed]

6. Tu X, Zhang F, Chen J, Tang M. Down syndrome burden in China and globally: A comparative analysis of 1990-2021 trends and future projections based on GBD 2021 database. Front Public Health. 2025;13:1632250.

   [Crossref] [Google Scholar] [PubMed]

7. Ptomey L, Hom C, Wilkins H, Doran E, Wright ST, Hoang D, et al. Alzheimer's disease research center Down syndrome cores: Experience from two sites. Alzheimers Dement. 2025;21(8):e70612.

   [Crossref] [Google Scholar] [PubMed]

8. Alanazi R, Alanazi AS, Alqazlan S, Benlaria H. Assessing the impact of AI tools on mobility and daily assistance for children with down syndrome in Saudi Arabia. Sci Rep. 2025;15(1):30826.

   [Crossref] [Google Scholar] [PubMed]

9. Yang SH, Park CG, Choi EK. Mediating effects of parental family adaptation on the quality of life of children with Down syndrome: A study of father-mother dyads. J Adv Nurs. 2025.

   [Crossref] [Google Scholar] [PubMed]

10. Joyner MJ. Exercise hyperemia, down syndrome and progress. Am J Physiol Heart Circ Physiol. 2025.

    [Crossref] [Google Scholar] [PubMed]